Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon …
T Yamatodani, L Ekblad, E Kjellén, A Johnsson… - Journal of cancer …, 2009 - Springer
Objective The aim of this study was to investigate the effect of epidermal growth factor
receptor (EGFR) blockade on cell survival and on downstream signalling pathways using …
receptor (EGFR) blockade on cell survival and on downstream signalling pathways using …
[HTML][HTML] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell …
R Hitt, A Irigoyen, H Cortes-Funes, JJ Grau… - Annals of …, 2012 - Elsevier
Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro
N Zhang, K Erjala, J Kulmala, X Qiu, M Sundvall… - Radiotherapy and …, 2009 - Elsevier
BACKGROUND AND PURPOSE: For locoregionally advanced HNSCC, chemoradiotherapy
with cisplatin or another platinum compound is considered as one of the standard treatment …
with cisplatin or another platinum compound is considered as one of the standard treatment …
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern …
AM Egloff, JW Lee, CJ Langer, H Quon, A Vaezi… - Clinical Cancer …, 2014 - AACR
Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …
Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent …
M Hara, H Nakanishi, K Tsujimura, M Matsui… - Cancer …, 2008 - Wiley Online Library
Cetuximab, a chimeric monoclonal antibody to epidermal growth factor receptor (EGFR), has
been proved to have clinically significant antitumor activity against advanced colorectal …
been proved to have clinically significant antitumor activity against advanced colorectal …
An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA)(FOLFOX-4) in the first-line treatment of patients with …
JM Tabernero, E Van Cutsem, J Sastre… - Journal of Clinical …, 2004 - ascopubs.org
3512 Background: Cetuximab (Erbitux) is an IgG1 monoclonal antibody targeting the EGFR,
shown to be effective in patients (pts) with EGFR-expressing metastatic CRC refractory to …
shown to be effective in patients (pts) with EGFR-expressing metastatic CRC refractory to …
A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients
F Becher, J Ciccolini, DC Imbs, C Marin, C Fournel… - Scientific Reports, 2017 - nature.com
Administration of first-in-class anti-EGFR monoclonal antibody cetuximab is contingent upon
extensive pharmacogenomic testing. However in addition to tumor genomics, drug exposure …
extensive pharmacogenomic testing. However in addition to tumor genomics, drug exposure …
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
M Hebbar, A Wacrenier, C Desauw, O Romano… - Anti-cancer …, 2006 - journals.lww.com
In patients with metastatic colorectal cancer, the use of cetuximab currently requires a
documented tumoral epidermal growth factor receptor positivity. Responses to cetuximab …
documented tumoral epidermal growth factor receptor positivity. Responses to cetuximab …
Epidermal growth factor receptor inhibitors in cancer treatment
F Ciardiello - Future Oncology, 2005 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with
tyrosine kinase enzymatic activity which plays a key role in human cancer. EGFR-dependent …
tyrosine kinase enzymatic activity which plays a key role in human cancer. EGFR-dependent …
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer
D Raben, B Helfrich, DC Chan, F Ciardiello… - Clinical Cancer …, 2005 - AACR
Purpose: The epidermal growth factor receptor (EGFR) overexpressed in approximately
80% of non-small cell lung cancers (NSCLC) is a target for novel therapeutics. Concurrent …
80% of non-small cell lung cancers (NSCLC) is a target for novel therapeutics. Concurrent …